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in Patients With Acute Coronary Syndromes
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Objectives This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome
(ACS) patients undergoing percutaneous coronary intervention (PCI).
Background The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate-
and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or
enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less major bleeding and similar ischemic out-
comes at 30 days. The impact of bivalirudin on 1-year outcomes in ACS patients undergoing PCI is unknown.
Methods In the ACUITY trial, 13,819 patients were enrolled, and 7,789 (56.4%) patients had PCI. Composite ischemia
(death, myocardial infarction, or unplanned revascularization) and mortality at 1 year were assessed.
Results Among patients undergoing PCI, 2,561, 2,609, and 2,619 were randomized to UFH or enoxaparin plus a GP IIb/
IIIa inhibitor, bivalirudin plus a GP IIb/IIIa inhibitor, and bivalirudin monotherapy, respectively. At 1 year, there
were no differences in composite ischemia (17.8% vs. 19.4% vs. 19.2%, p  NS) or mortality (3.2% vs. 3.3% vs.
3.1%, p  NS) among the 3 groups, respectively.
Conclusions Bivalirudin compared with UFH or enoxaparin plus a GP IIb/IIIa inhibitor results in similar rates of composite
ischemia and mortality at 1 year in moderate- and high-risk ACS patients undergoing PCI. (J Am Coll Cardiol
2008;52:807–14) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.036s
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The ACUITY Trial: 1-Year Results September 2, 2008:807–14In patients with moderate- and
high-risk non–ST-segment ele-
vation acute coronary syndromes
(NSTE-ACS), an early invasive
strategy of angiography and sub-
sequent coronary revasculariza-
tion coupled with an antithrom-
botic regimen has been shown to
improve long-term outcomes (1–
4). The American College of
Cardiology/American Heart As-
sociation and the European So-
ciety of Cardiology guidelines
recommend initiation of anti-
platelet therapy (aspirin and clo-
pidogrel), unfractionated heparin
(UFH), or low-molecular-weight
heparin and glycoprotein (GP)
IIb/IIIa inhibitors for NSTE-
ACS patients undergoing percu-
taneous coronary intervention
(PCI) (5,6). Although this inten-
sive antiplatelet and antithrom-
bin regimen reduces ischemic
vents, such treatment regimens are often associated with an
ncreased risk of bleeding, a complication that is strongly
ssociated with early and late mortality (7–11).
Bivalirudin is a direct thrombin inhibitor that has several
dvantages over heparin. Bivalirudin inhibits both circulat-
ng and clot-bound thrombin, does not activate platelets,
nd has a short, 25-min half-life that allows for a rapid
eturn to hemostasis (12). In the REPLACE-2 (Random-
zed Evaluation in PCI Linking Angiomax to Reduced
linical Events) trial, treatment with bivalirudin and pro-
isional GP IIb/IIIa inhibitor use (in 7% of patients) in
atients undergoing PCI provided similar protection from
schemic events as heparin plus routine use of GP IIb/IIIa
nhibitors, but with a significant 41% relative reduction in
ajor bleeding (13). At 1 year, there was a trend toward
educed mortality in the bivalirudin group, a benefit that
as greatest in high-risk patient subgroups (5,14). The
007 American College of Cardiology/American Heart
ssociation guidelines provide a class I recommendation for
se of bivalirudin monotherapy in patients with acute
oronary syndromes (ACS) undergoing PCI (5).
The ACUITY (Acute Catheterization and Urgent Inter-
ention Triage StrategY) trial randomized 13,819 patients
ith moderate- and high-risk NSTE-ACS to UFH or
eceived consulting fees from The Medicines Company, Bristol-Myers Squibb,
chering-Plough, and Sanofi-Aventis, and lecture fees from The Medicines Company
nd Nycomed. Dr. Mehran has received lecture fees from The Medicines Company,
ordis, and Boston Scientific. Dr. Moses has received consulting fees from Johnson
Johnson and is on the Speakers’ Bureau for AstraZeneca.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft
CI  confidence interval
GP  glycoprotein
HR  hazard ratio
IV  intravenous
LMWH  low-molecular-
weight heparin
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
coronary syndromes
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparinu
Manuscript received December 12, 2007; revised manuscript received May 21,
008, accepted May 27, 2008.noxaparin plus a GP IIb/IIIa inhibitor, bivalirudin plus a
P IIb/IIIa inhibitor, or bivalirudin alone. Treatment with
ivalirudin monotherapy was associated with similar rates of
omposite ischemia but significantly reduced bleeding com-
lications compared with UFH or enoxaparin plus a GP
Ib/IIIa inhibitor (15). Thirty-day outcomes in the patients
ndergoing PCI were consistent with the overall findings,
ith comparable ischemic outcomes and 48% less major
leeding with bivalirudin monotherapy (16).
The impact of a bivalirudin-alone strategy as compared
ith UFH/enoxaparin plus a GP IIb/IIIa inhibitor on
ong-term ischemia outcomes and mortality in moderate-
nd high-risk ACS patients undergoing PCI has not been
eported. Therefore, we assessed the incidence of ischemic
utcomes at 1 year in patients in the ACUITY trial
ndergoing PCI. In addition, we examined 1-year mortality
cross multiple prespecified subgroups.
ethods
he design of the ACUITY trial has been described
reviously (17). In brief, patients age 18 years or older with
ymptoms of unstable angina lasting 10 min within 24 h
ere eligible if they met 1 or more of the following criteria:
ew ST-segment depression or transient elevation 1 mm;
levated troponin I, troponin T, or creatine kinase-
yocardial band; known coronary artery disease, or all 4
ther Thrombolysis In Myocardial Infarction (TIMI) risk
riteria (18). Exclusion criteria included acute ST-segment
levation myocardial infarction (MI) or shock; bleeding
iathesis or major bleeding within 2 weeks; thrombocyto-
enia; creatinine clearance 30 ml/min; or recent admin-
stration of abciximab, warfarin, fondaparinux, fibrinolytic
gents, bivalirudin, or 1 dose of low-molecular-weight
eparin. The study was approved by institutional review
oards or ethics committees at each center, and all patients
ave written informed consent.
andomization and study procedures. The ACUITY
rial randomized 13,819 patients to receive UFH or enox-
parin with a GP IIb/IIIa inhibitor, bivalirudin plus a GP
Ib/IIIa inhibitor, or bivalirudin alone. The UFH was
dministered as a 60 IU/kg intravenous (IV) bolus followed
y an infusion of 12 IU/kg/h to target an activated partial
hromboplastin time of 50 to 75 s before angiography and
n activated clotting time of 200 to 250 s during PCI.
noxaparin 1 mg/kg subcutaneous twice daily was initiated
efore angiography, with an additional 0.3 mg/kg or 0.75
g/kg IV bolus given before PCI if the most recent
ubcutaneous dose had been given more than 8 or 16 h
arlier, respectively. Bivalirudin was administered as a 0.1
g/kg IV bolus and an infusion of 0.25 mg/kg/h. An
dditional IV bolus of 0.5 mg/kg was administered before
CI, and the infusion was increased to 1.75 mg/kg/h.
Patients assigned to one of the GP IIb/IIIa inhibitor arms
ere further randomized in a 2 2 factorial design to either
pstream GP IIb/IIIa inhibitor initiation immediately after
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September 2, 2008:807–14 The ACUITY Trial: 1-Year Resultsandomization or to deferred initiation for selected use in
he catheterization laboratory starting immediately before
CI. In accordance with current guidelines (5,6), either
ptifibatide or tirofiban, per the investigator’s choice, was
ermitted for upstream use and continued through PCI.
ither abciximab or eptifibatide was permitted for deferred
se initiated in the catheterization laboratory. In patients
andomized to deferred use of GP IIb/IIIa inhibitors or to
ivalirudin monotherapy, provisional use was permitted
efore angiography for severe breakthrough ischemia and
uring PCI in bivalirudin monotherapy patients for pre-
pecified procedural complications (16,17).
Per protocol, angiography was intended in all patients
ithin 72 h of randomization with subsequent triage to
CI, coronary artery bypass graft (CABG) surgery, or
edical management. Aspirin was administered daily dur-
ng hospitalization (300 to 325 mg orally or 250 to 500 mg
V). Although timing and initial dosing of clopidogrel were
eft to the investigator’s discretion, a loading dose of 300 mg
r more was required within 2 h after PCI in all cases.
lopidogrel (75 mg daily) was recommended for 1 year in
ll patients undergoing PCI, and aspirin (75 to 25 mg daily)
as recommended indefinitely.
nd points and statistical analyses. End points were
ssessed at 30 days and 1 year. Pre-specified 30-day primary
nd points in the trial were composite ischemia, defined as
eath, MI, or unplanned revascularization for ischemia;
on-CABG ACUITY-scale major bleeding; and net clini-
al outcome (composite ischemia or non-CABG ACUITY-
Figure 1 Enrollment and Randomization of the ACUITY Trial
ACS  acute coronary syndromes; CABG  coronary artery bypass graft surgery;
GP  glycoprotein; PCI  percutaneous coronary intervention; UFH  unfractionatcale major bleeding). Non-CABG ACUITY-scale major
leeding was defined as intracranial or intraocular bleeding,
ccess site hemorrhage requiring intervention, hematoma
5 cm in diameter, reduction in hemoglobin of 3 g/dl
ith an overt bleeding source or 4 g/dl with no source
dentified, reoperation for bleeding, or blood product trans-
usion. Only composite ischemia was evaluated after 30
ays. All 30-day and 1-year primary end points were
djudicated by a blinded Clinical Events Committee.
Analyses of 1-year composite ischemia and mortality in
atients undergoing PCI were pre-specified. Analysis was
erformed using time-to-event data (with patients censored at
he time of withdrawal from the study or last follow-up),
isplayed using Kaplan-Meier methodology, and compared
ith the log-rank test. Hazard ratios (HRs) with 95% confi-
ence intervals (CIs) are presented for treatment comparisons.
The effect of treatment assignment on 1-year mortality and
omposite ischemia was tested in multiple subgroups using
ormal interaction testing. A 2-sided  0.05 was used for all
uperiority testing. The impact of the timing of clopidogrel
dministered on 1-year mortality was also evaluated.
esults
tudy population and clinical outcomes. Patient dispo-
ition is presented in Figure 1. Baseline characteristics
Table 1) were similar among the 3 treatment groups.
etails of study medication administration and procedural
etails have been published previously (16).
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The ACUITY Trial: 1-Year Results September 2, 2008:807–14The median time from randomization to PCI was 4.9 h
n the heparin plus GP IIb/IIIa group, 4.9 h in the
ivalirudin plus GP IIb/IIIa inhibitor group, and 5.1 h in
he bivalirudin monotherapy group. Major bleeding oc-
urred in 7% of the UFH/enoxaparin plus GP IIb/IIIa
nhibitor group and 4% in the bivalirudin group, p 
.0001. Patients experiencing a major bleed had a signifi-
antly longer hospital stay than those without a major bleed
5.0 days vs. 3.0 days, respectively, p  0.0001). No
ifferences were observed in rates of composite ischemia or
ortality at 1 year in those who received bivalirudin with or
ithout a GP IIb/IIIa inhibitor compared with those who
eceived UFH or enoxaparin plus a GP IIb/IIIa inhibitor
Table 2). At 1 year, 82, 85, and 80 patients had died in the
FH or enoxaparin plus GP IIb/IIIa inhibitor, bivalirudin
lus GP IIb/IIIa inhibitor, and bivalirudin monotherapy
aseline Characteristics of Patients Undergoing PCI
Table 1 Baseline Characteristics of Patients Undergoing PCI
Heparin
 G
(
Age, median [range], yrs
Gender (male)
Weight, median [IQR], kg
Diabetes
Insulin-requiring
Hypertension 1,
Hyperlipidemia 1,
Current smoker
Prior MI
Prior PCI
Prior CABG
Renal insufficiency*
Baseline high-risk features
Elevated cardiac biomarker or ST-segment deviation 1 mm 1,
Elevated cardiac biomarker (CK-MB or troponin) 1,
Elevated troponin 1,
Baseline ST-segment deviation 1 mm
TIMI risk score
0–2
3–4 1,
5–7
Calculated creatinine clearance using the Cockcroft-Gault equation 60 ml/min.
CABG coronary artery bypass graft; CK-MB creatine kinase-myocardial band; GP glycoprote
hrombolysis In Myocardial Infarction; UFH  unfractionated heparin.
linical Outcomes at 1 Year in Patients Undergoing PCI
Table 2 Clinical Outcomes at 1 Year in Patients Undergoing PC
Heparin
(UFH or Enoxaparin)
 GP IIb/IIIa Inhibitor
(n  2,561) (%)
Bivalirudin
 GP IIb/IIIa Inhibitor
(n  2,609) (%)
Composite ischemia 456 (17.8) 507 (19.4)
Death from any cause 82 (3.2) 85 (3.3)
Myocardial infarction 201 (7.8) 237 (9.1)
Unplanned revascularization
for ischemia
292 (11.4) 326 (12.5)
Comparison between bivalirudin plus a GP IIb/IIIa inhibitor and heparin (UFH or enoxaparin) plus
Ib/IIIa inhibitor.
CI  confidence interval; other abbreviations as in Table 1.rms, respectively. Between 30 days and 1 year, 58, 55, and
2 patients died in the 3 groups, respectively.
The interaction p value for patients treated with PCI
ersus patients in the overall ACUITY trial is p  0.592 for
he 3 groups and p  0.701 for bivalirudin versus UFH/
noxaparin plus GP IIb/IIIa antagonist. The incidence of
omposite ischemia for upfront use of GP IIb/IIIa antago-
ists versus in-lab use was 17.2% versus 18.4%, p  0.439
or UFH/enoxaparin and 17.4% versus 21.5%, p  0.009
or bivalirudin; and for death 3.1% versus 3.3%, p 
.0870 for UFH/enoxaparin and 2.8% versus 3.7%, p 
.209 for bivalirudin.
Results were similar in patients previously treated with
FH or enoxaparin and switched to bivalirudin mono-
herapy at randomization. There were no significant differ-
nces in rates of 1-year mortality (2.7% vs. 2.9% [HR: 0.93,
or Enoxaparin)
IIIa Inhibitor
,561) (%)
Bivalirudin
 GP IIb/IIIa Inhibitor
(n  2,609) (%)
Bivalirudin
Alone
(n  2,619) (%)
5–91] 62 [21–95] 63 [30–92]
(72.6) 1,919 (73.6) 1,919 (73.3)
3, 96] 84 [74, 96] 84 [75, 95]
,543 (27.6) 713/2,595 (27.5) 721/2,603 (27.7)
03 (29.2) 208/713 (29.2) 224/721 (31.1)
,546 (65.7) 1,690/2,594 (65.2) 1,714/2,611 (65.6)
,519 (55.9) 1,440/2,555 (56.4) 1436/2566 (56.0)
,507 (30.7) 797/2,563 (31.1) 795/2,571 (30.9)
,506 (30.4) 760/2,549 (29.8) 798/2,565 (31.1)
,545 (38.5) 978/2,585 (37.8) 1030/2,596 (39.7)
,555 (17.3) 450/2,605 (17.3) 468/2,613 (17.9)
,534 (5.4) 156/2,579 (6.0) 158/2,599 (6.1)
,441 (76.8) 1,886/2,506 (75.3) 1,931/2,508 (77.0)
,376 (65.1) 1,555/2,439 (63.8) 1,626/2,450 (66.4)
,215 (64.8) 1,447/2,308 (62.7) 1,513/2,285 (66.2)
,559 (35.4) 958/2,608 (36.7) 923/2,618 (35.3)
,262 (16.7) 357/2,328 (15.3) 376/2,346 (16.0)
,262 (52.1) 1,272/2,328 (54.6) 1,248/2,346 (53.2)
,262 (31.2) 699/2,328 (30.0) 722/2,346 (30.8)
 interquartile ratio; MImyocardial infarction; PCI percutaneous coronary intervention; TIMI
Hazard Ratio
(95% CI)
p
Value*
Bivalirudin Alone
(n  2,619) (%)
Hazard Ratio
(95% CI)
p
Value†
.11 (0.98–1.26) 0.11 502 (19.2) 1.09 (0.96–1.23) 0.19
.02 (0.75–1.38) 0.91 80 (3.1) 0.95 (0.70–1.30) 0.76
.17 (0.97–1.41) 0.10 244 (9.3) 1.19 (0.99–1.44) 0.06
.11 (0.94–1.29) 0.21 310 (11.8) 1.04 (0.89–1.22) 0.63
/IIIa inhibitor. †Comparison between bivalirudin alone and heparin (UFH or enoxaparin) plus a GP(UFH
P IIb/
n  2
63 [2
1,850
84 [7
703/2
205/7
673/2
409/2
770/2
761/2
979/2
442/2
136/2
874/2
547/2
436/2
907/2
377/2
179/2
706/2I
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September 2, 2008:807–14 The ACUITY Trial: 1-Year Results5% CI: 0.58 to 1.48], p  0.75) or composite ischemia
18.0% vs. 18.4% [HR: 0.99, 95% CI: 0.82 to 1.19], p 
.89) compared with rates in patients who received consis-
ent therapy with UFH or enoxaparin.
Treatment effects with respect to composite ischemia
ere consistent across multiple subgroups examined, with
he exception of the impact of clopidogrel administration.
owever, no interaction was observed with respect to
ortality (Figs. 3A and 3B). No significant interactions
or composite ischemia or mortality were noted with
egard to age, gender, diabetic status, renal function,
aseline risk (elevated creatine kinase-myocardial band/
roponin, ST-segment deviations, and TIMI risk scores),
nd time to intervention.
iscussion
his analysis of patients undergoing PCI from the
CUITY trial demonstrates that, in addition to signifi-
antly less bleeding at 30 days, treatment with bivalirudin
onotherapy yields comparable 1-year composite isch-
mia and mortality compared with UFH or enoxaparin
lus a GP IIb/IIIa inhibitor. These findings were ob-
erved regardless of the timing of thienopyridine pre-
reatment, baseline high-risk characteristics, and prior
ntithrombin treatment.
These results are consistent with the overall ACUITY
rial, in which bivalirudin monotherapy (with provisional
se of GP IIb/IIIa inhibitors in 10% of patients) resulted
n similar rates of composite ischemia and mortality at 1
ear (20). In the current study, mortality was similar in the
Figure 2 Time to Death
Time-to-event curve comparing patients randomized to heparin (unfractionated or e
GP IIb/IIIa inhibitors, and bivalirudin monotherapy for mortality with a log-rank p vaivalirudin and heparin plus GP IIb/IIIa arms despite the u1% reduction in bleeding with bivalirudin and the signif-
cant association of major bleeding with 1-year mortality.
his is not surprising given that the ACUITY trial was
tatistically powered for 30-day composite ischemia and
leeding end points, not for mortality at 12 months. A
ubstantially larger study would have been required to show
n effect of bleeding. Further, the numerical difference in
I would not be expected to differentially affect mortality
mong treatment arms.
The reduced rates of major bleeding after PCI with
ivalirudin is an important finding, as multiple studies
7–10) have reported a strong association between bleed-
ng complications in ACS and in PCI with mortality. In
he REPLACE-2 trial in elective and lower-risk ACS
atients undergoing PCI (21), which showed that there
ere significantly higher mortality rates at 30 days, 6
onths, and 1 year in patients who had major bleeding
ompared with those who did not, major bleeding was an
ndependent predictor of 1-year mortality (odds ratio:
.66, 95% CI: 1.44 to 4.92, p  0.002). In the overall
CUITY trial, major bleeding was an independent pre-
ictor of 30-day mortality (odds ratio: 7.55, 95% CI 4.68
o 12.18, p  0.0001) (11).
The findings of the present analysis were consistent
cross multiple subgroups, including patients with high-
isk baseline characteristics, diabetes, and renal insuffi-
iency. These data also suggest that long-term survival
fter bivalirudin in patients with ACS undergoing PCI is
ot dependent on the timing of clopidogrel administra-
ion. No interaction existed for mortality and clopidogrel
arin) plus GP IIb/IIIa inhibitors, bivalirudin plus
ox  enoxaparin; other abbreviations as in Figure 1.noxap
lue. Ense, and the interaction observed for composite ischemia
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The ACUITY Trial: 1-Year Results September 2, 2008:807–14eemed to be largely driven by patients who did not
eceive clopidogrel.
Many patients with NSTE-ACS are initiated on an
ntithrombin agent either in a transferring hospital or in
he emergency department before angiography (22). In
he SYNERGY (Superior Yield of the New Strategy of
noxaparin, Revascularization and Glycoprotein IIb/IIIa
nhibitors) trial (22), there was no difference in ischemic
utcomes between enoxaparin and UFH, but significantly
ore bleeding in the enoxaparin arm. In the SYNERGY
rial, crossover from UFH to enoxaparin or vice versa was
ssociated with increased bleeding rates. However in the
Figure 3 Mortality and Composite Ischemia in Subgroups
Comparison of mortality (A) and composite ischemia (B) in patients randomly ass
displayed as risk ratio (RR) (black boxes) with 95% CI (horizontal lines). CI  confide
able and the relative treatment effect; TIMI  Thrombolysis In Myocardial Infarction; oEPLACE-2 trial, patients who switched at the time of bandomization from UFH or enoxaparin to bivalirudin
ad no increase in bleeding (23). Conversely, in patients
andomized to receive UFH plus GP IIb/IIIa inhibitors,
re-treatment with either UFH or enoxaparin was asso-
iated with increased major and minor bleeding as well as
ransfusions. In the present analysis, a protocol-
andated switch at randomization to bivalirudin mono-
herapy from prior UFH or enoxaparin resulted in similar
-year mortality rates of 2.9% versus 2.7% in patients
reated with bivalirudin monotherapy compared with
FH or enoxaparin plus GP IIb/IIIa inhibition. These
ndings demonstrate that patients undergoing PCI can
to UFH or enoxaparin plus a GP IIb/IIIa inhibitor versus bivalirudin monotherapy,
terval; CrCl  creatinine clearance; pint  value for the interaction between the vari-
breviations as in Figure 1. Continued on next page.igned
nce in
ther abe safely switched to bivalirudin monotherapy from UFH
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September 2, 2008:807–14 The ACUITY Trial: 1-Year Resultsr enoxaparin, gaining the advantage of an approximate
3% reduction in bleeding with bivalirudin in patients
ndergoing PCI without increasing 30-day ischemic
vents or long-term mortality (16).
Prevention of major bleeds may also translate into a
eduction in hospital costs. In the present analysis, PCI
atients experiencing a major bleed had a significantly
onger hospital stay compared with those who did not
leed. An analysis of the REPLACE-2 trial (23) found
hat treatment with bivalirudin with provisional use of
P IIb/IIIa inhibitors resulted in a $405 and $374
eduction in in-hospital and 30-day costs, respectively,
ompared with heparin plus a GP IIb/IIIa inhibitor.
ospital savings were due primarily to reductions in
Figure 3 Continuedajor bleeding ($107 per patient). Given the large oumber of PCI procedures performed in the U.S. (1
illion/year) (24), even modest cost savings on a per
atient basis have the potential to result in substantial
avings to the health care system.
tudy limitations. The decision to perform PCI occurred
ollowing randomization; however, the baseline charac-
eristics of the 3 groups were well matched, and an
nvasive strategy was part of the design of the trial. The
CI cohort was underpowered for noninferiority testing
nd subgroups, and all analyses should be considered
ypothesis-generating. Also, the study design was open-
abel, and bias may have occurred in assessment of end
oints. This is mitigated to some extent by all end points
eing adjudicated by a blinded events committee with
riginal source documents.
CI
i
b
a
u
i
e
a
t
r
t
a
r
A
T
t
s
F
R
G
P
H
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
814 White et al. JACC Vol. 52, No. 10, 2008
The ACUITY Trial: 1-Year Results September 2, 2008:807–14onclusions
n patients with moderate- and high-risk ACS undergo-
ng PCI, bivalirudin alone results in significantly less
leeding at 30 days and comparable composite ischemia
nd mortality at 1 year compared with heparin (either
nfractionated or enoxaparin) plus a GP IIb/IIIa inhib-
tor. These results were consistent across all subgroups
xamined regardless of patient risk, exposure to prior
ntithrombin therapy, or timing of clopidogrel adminis-
ration. These findings, together with the significant
eduction in bleeding at 30 days, make bivalirudin rather
han UFH or enoxaparin plus a GP IIb/IIIa inhibitor an
ttractive antithrombotic choice for moderate- and high-
isk ACS patients undergoing PCI.
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